MX2008006440A - Usos terapeuticos de compuestos esteroideos. - Google Patents

Usos terapeuticos de compuestos esteroideos.

Info

Publication number
MX2008006440A
MX2008006440A MX2008006440A MX2008006440A MX2008006440A MX 2008006440 A MX2008006440 A MX 2008006440A MX 2008006440 A MX2008006440 A MX 2008006440A MX 2008006440 A MX2008006440 A MX 2008006440A MX 2008006440 A MX2008006440 A MX 2008006440A
Authority
MX
Mexico
Prior art keywords
pain
further characterized
hydrogen atom
use according
hydroxy group
Prior art date
Application number
MX2008006440A
Other languages
English (en)
Spanish (es)
Inventor
Ernst Wuelfert
James Robert Murray
David Wynick
Original Assignee
Hunter Fleming Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunter Fleming Ltd filed Critical Hunter Fleming Ltd
Publication of MX2008006440A publication Critical patent/MX2008006440A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
MX2008006440A 2005-11-18 2006-11-17 Usos terapeuticos de compuestos esteroideos. MX2008006440A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0523550.2A GB0523550D0 (en) 2005-11-18 2005-11-18 Therapeutic uses of steroidal compounds
PCT/GB2006/004305 WO2007057691A2 (en) 2005-11-18 2006-11-17 Therapeutic uses of steroidal compounds

Publications (1)

Publication Number Publication Date
MX2008006440A true MX2008006440A (es) 2008-12-01

Family

ID=35580318

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008006440A MX2008006440A (es) 2005-11-18 2006-11-17 Usos terapeuticos de compuestos esteroideos.

Country Status (16)

Country Link
US (1) US8846652B2 (https=)
EP (1) EP1948192A2 (https=)
JP (1) JP5395437B2 (https=)
KR (1) KR101314694B1 (https=)
CN (1) CN101346144B (https=)
AU (1) AU2006314226B2 (https=)
CA (1) CA2630441C (https=)
GB (1) GB0523550D0 (https=)
IL (1) IL191457A (https=)
MX (1) MX2008006440A (https=)
NO (1) NO20082741L (https=)
NZ (1) NZ568560A (https=)
RU (1) RU2427375C2 (https=)
TW (1) TWI386211B (https=)
WO (1) WO2007057691A2 (https=)
ZA (1) ZA200804266B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20110244A7 (es) 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
CN108434090A (zh) * 2017-02-14 2018-08-24 高药品股份有限公司 以生理脂肪为基剂的类固醇药膏
RU2745868C9 (ru) * 2020-05-28 2021-04-08 Федеральное государственное бюджетное образовательное учреждение высшего образования «Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва» Способ ускорения регенерационных процессов в поврежденных периферических нервах

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012997A1 (en) 1991-01-16 1992-08-06 The General Hospital Corporation Human galanin
WO1992015015A1 (en) 1991-02-25 1992-09-03 Zymogenetic, Inc. Methods for detecting galanin antagonists
DE69225706T2 (de) 1991-03-06 1998-11-26 Garvan Institute Of Medical Research, Darlinghurst, Neu Sued Wales/New South Wales Humanes galanin, cdna-klone die für humanes galanin kodieren und eine methode humanes galamin herzustellen
SE9101472D0 (sv) 1991-05-15 1991-05-15 Trion Forskning & Utveckling Galanin antagonist
JPH06172387A (ja) 1992-12-11 1994-06-21 Aibaitsu Kk 合成ペプチド誘導体
EP0698612B1 (en) * 1993-05-18 2001-07-25 Ltt Institute Co., Ltd. Osteogenesis promoter and osteoporosis remedy
JPH09151197A (ja) * 1995-11-29 1997-06-10 L T T Kenkyusho:Kk 自己免疫疾患治療薬
DE69739760D1 (de) 1996-07-24 2010-03-25 Neurotargets Ltd Verwendung eines Galanin-agonisten in der Herstellung eines Medikaments zur Verbesserung des Gedächtnisses und anderer cognitiver Funktionen
JP2000169374A (ja) * 1998-12-03 2000-06-20 Ltt Kenkyusho:Kk Ｉｇｆ増強剤
TR200200406T2 (tr) * 1999-06-11 2002-06-21 Watson Pharmaceuticals, Inc. Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması
DE10054294A1 (de) * 2000-11-02 2002-05-16 Heinrich Wieland Topische Behandlung bei der Mastalgie
GB0105772D0 (en) * 2001-03-08 2001-04-25 Sterix Ltd Use
DE60120104T2 (de) 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
WO2002096934A1 (en) 2001-05-25 2002-12-05 Kemia, Inc. Non-natural galanin receptor ligands
DK1406606T3 (da) 2001-07-16 2007-03-05 Ortho Mcneil Pharm Inc Carbamatforbindelser til forebyggelse eller behandling af neuropatisk smerte og smerte forbundet med klynge- og migrænehovedpine
JP2004538305A (ja) 2001-07-31 2004-12-24 ファルマシア・アンド・アップジョン・カンパニー ３−ヘテロシクリル−及び３−シクロアルキル−３−アリールオキシプロパンアミンによる慢性疼痛の治療
WO2003011272A1 (en) 2001-07-31 2003-02-13 Pharmacia & Upjohn Company Treatment of chronic pain with 3-aryloxy-3-phenylpropanamines
ATE332688T1 (de) 2001-10-16 2006-08-15 Endo Pharmaceuticals Inc Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
GB0403509D0 (en) 2004-02-17 2004-03-24 Neuro Targets Ltd Galanin receptors and brain injury
US20070231373A1 (en) * 2004-04-28 2007-10-04 Hunter-Fleming Limited Transdermal Steriod for Formulation
JP5449775B2 (ja) * 2005-10-19 2014-03-19 チャバフ ピーティーワイ エルティーディー 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減
WO2008065408A2 (en) 2006-11-30 2008-06-05 Hunter-Fleming Limited Modulation of prostaglandin/cyclooxygenase metabolic pathways

Also Published As

Publication number Publication date
US8846652B2 (en) 2014-09-30
RU2008124834A (ru) 2009-12-27
JP5395437B2 (ja) 2014-01-22
WO2007057691A2 (en) 2007-05-24
TW200730180A (en) 2007-08-16
NZ568560A (en) 2010-11-26
CN101346144A (zh) 2009-01-14
IL191457A (en) 2013-10-31
AU2006314226A1 (en) 2007-05-24
WO2007057691A3 (en) 2007-08-02
CA2630441C (en) 2013-10-29
CN101346144B (zh) 2011-07-20
US20090227551A1 (en) 2009-09-10
ZA200804266B (en) 2009-01-28
CA2630441A1 (en) 2007-05-24
GB0523550D0 (en) 2005-12-28
JP2009515939A (ja) 2009-04-16
TWI386211B (zh) 2013-02-21
IL191457A0 (en) 2009-08-03
KR101314694B1 (ko) 2013-10-07
NO20082741L (no) 2008-07-23
KR20080073755A (ko) 2008-08-11
RU2427375C2 (ru) 2011-08-27
EP1948192A2 (en) 2008-07-30
AU2006314226B2 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
Zhang et al. Cerebral mast cells contribute to postoperative cognitive dysfunction by promoting blood brain barrier disruption
Gauthaman et al. Aphrodisiac properties of Tribulus Terrestris extract (Protodioscin) in normal and castrated rats
US9034826B2 (en) Use of epidermal growth factor for the morphofunctional restoration of peripheral nerves in diabetic neuropathy
AU2003250892B2 (en) Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors
AT506095A1 (de) Verwendung von proteasen
Wang et al. Human breast milk-derived exosomes protect against intestinal ischemia and reperfusion injury in neonatal rats
CN1951410A (zh) 含药用人参的脑细胞或神经细胞保护剂
US20100152150A1 (en) The application of marine steroid in preparing the medicine of treating neurons damaging
JP3623501B2 (ja) インターロイキン−１阻害化合物による神経病学的状態の治療
McNeil et al. Reversal of ethanol and indomethacin‐induced suppression of hepatic DNA synthesis by 16, 16‐dimethyl prostaglandin E2
IL191457A (en) Use of the history of androstene – 17,3 – discussion for the preparation of the drug for the treatment of neuropathic pain
JP4942905B2 (ja) 神経保護活性を有する７−ヒドロキシエピアンドロステロン
JP2009515939A5 (https=)
DE60017793T2 (de) Verfahren zur vorbeugung und behandlung von beschädigungen des schleimhautgewebes
CN116919932A (zh) 成骨剂及其用途
KR20210058586A (ko) 실데나필 및 rock 저해제를 포함하는 뇌졸중 치료용 약학적 조성물
KR101277873B1 (ko) Ｎｉｎｊｕｒｉｎ 활성 억제제를 포함하는 신경세포 또는 내피세포 재생용 조성물
WO2007123234A1 (ja) 抗てんかん作用増強剤
JP3713271B2 (ja) ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンの浮腫および痛みの治療のための使用
KR101936836B1 (ko) 허혈성 뇌질환의 예방 또는 치료용 약학적 조성물
JP3713271B6 (ja) ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンの浮腫および痛みの治療のための使用
JPS63218626A (ja) 自己免疫性腸疾患治療剤
EP1875923A2 (en) Use of fractalkine for the production of a neuroprotector drug against cell death
JPH08310967A (ja) 脳組織損傷の治療または予防剤
Roze Cyclosporine in canine ophthalmology.

Legal Events

Date Code Title Description
FG Grant or registration